✨ Free AI Report
GeoVax Labs, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GeoVax Labs, Inc.
Company Research

GeoVax Labs, Inc.: Business Overview, Financials & Competitive Analysis

GeoVax Labs, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Early-stage vaccine developer with diversified infectious disease and oncology pipeline, but severe capital constraints and lack of revenue limit near-term viability. GeoVax had approximately $5 million in cash at the end of Q3 2025 with high cash burn rates from R&D, increasing the likelihood of future stock offerings and.

What is GeoVax Labs, Inc.'s industry? GeoVax Labs, Inc. (geovax.com) operates in Vaccines. AskCyborg classifies GeoVax Labs, Inc. under Vaccines in its company registry.

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies targeting serious infectious diseases and solid tumor cancers. The company's lead program is GEO-CM04S1, a...

3/ 10Challenged

Cyborg Score thesis

Early-stage vaccine developer with diversified infectious disease and oncology pipeline, but severe capital constraints and lack...

Read the full analyst-debate transcript →
Industry Vaccines
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest GeoVax Labs, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GeoVax Labs, Inc.

AskCyborg analysts argue the bull and bear cases for GeoVax Labs, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GeoVax Labs, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GeoVax Labs, Inc. Overview

Pro stress-test →

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies targeting serious infectious diseases and solid tumor cancers. The company's lead program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in Phase 2b clinical trials supported by a BARDA-funded contract. The company faces significant capital constraints and is dependent on government funding and strategic partnerships for advancement.

Strategic Profile

Pro stress-test →

GeoVax develops vaccines and immunotherapies using a modified vaccinia ankara virus-like particle vaccine platform. Development programs focus on vaccines against COVID-19, hemorrhagic fever viruses, malaria, zika, and HIV, as well as immunotherapy programs targeting tumor-associated antigen MUC1 and HPV-induced cancers. As a pre-commercial clinical-stage company, GeoVax relies on government contracts and institutional partnerships rather than traditional commercial revenue streams.

Competitive Landscape

Pro stress-test →

GeoVax competes in the vaccine development space against larger, better-capitalized biotechnology and pharmaceutical companies developing next-generation COVID-19 vaccines and therapeutic vaccines for infectious diseases. Competitors include clinical-stage vaccine developers like Evaxion, iBio, and larger pharmaceutical companies with vaccine divisions. GeoVax's distinct MVA-VLP platform and focus on immunocompromised populations and immuno-oncology represent differentiation, but capital limitations significantly constrain competitive positioning.

Industry Context

GeoVax Labs, Inc. operates in Vaccines.

Key facts

Founded: 1999 · Headquarters: Smyrna, US · Employees: N/A · Revenue: Pre-revenue (grant-funded) · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for GeoVax Labs, Inc..

  • GEO-CM04S1 is being advanced in Phase 2 trials across three patient populations: primary vaccine for immunocompromised patients, booster for chronic lymphocytic leukemia patients, and booster for healthy adults previously vaccinated with mRNA vaccines.
  • Primary funding sources come from governmental agencies and academic/research institutions through collaboration agreements rather than traditional commercial customers.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2025Completed $2.5 million registered direct offering to healthcare-focused institutional investors
  • July 2025Initiated research program with Vaxxas for needle-free microarray patch delivery of GEO-MVA vaccines
  • +1 moreTrack every material event for GeoVax Labs, Inc. as it happens. Explore monitoring →
Get alerted when GeoVax Labs, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Next-generation COVID-19 vaccinesmRNA-based vaccines and therapeutics→Viral vector vaccinesDNA-based vaccine and immunotherapy platform→Clinical-stage vaccine developmentAI-driven therapeutic vaccine development→Therapeutic vaccine platformsPlant-derived vaccine and therapeutic protein production→

Compare GeoVax Labs, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GeoVax Labs, Inc. operates in Vaccines. See how the rest of the sector scores on the Cyborg framework.

Browse Vaccines research →
NEW · MCP server

Ask your AI assistant about GeoVax Labs, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GeoVax Labs, Inc. and its top competitor on Cyborg Score”
“What did GeoVax Labs, Inc. do this quarter?”
“Is GeoVax Labs, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GeoVax Labs, Inc. do?+
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies targeting serious infectious diseases and solid tumor cancers. The company's lead program is GEO-CM04S1, a...
What is GeoVax Labs, Inc.'s Cyborg Score?+
GeoVax Labs, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GeoVax Labs, Inc.'s main competitors?+
Named competitors include Next-generation COVID-19 vaccines, Viral vector vaccines, Clinical-stage vaccine development, Therapeutic vaccine platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full GeoVax Labs, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GeoVax Labs, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GeoVax Labs, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.